Further, there was a trend towards significance for improved PFS in patients with F158V polymorphisms when conatumumab was used in in combination with other agents [ 122 ].
← all excerpts
Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy.
1
—
—